The safety of albiglutide for the treatment of type 2 diabetes

Marc S. Rendell

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Introduction: Albiglutide is a marketed long acting GLP-1 receptor agonist (GLP-1 RA) administered by weekly injection. It has significantly less gastrointestinal side effects than other GLP-1 RAs in current use but does not improve HbA1c or promote weight loss to the same extent as competitor agents such as liraglutide. Area Covered: The safety of albiglutide is discussed. The review encompassed a search of PubMed and a thorough analysis of the European Union and US Food and Drug Administration approval documents. Expert Opinion: Unlike competitor agents, the gastrointestinal side effects of albiglutide are not much greater than placebo. It has been studied and appears safe at all stages of renal failure. There exists concern about an imbalance of pancreatitis cases in the approval program as well as injection site reactions which led to discontinuance of therapy in up to 2% of participants. A large long term study now underway will determine if albiglutide, with its relatively favorable GI tolerance, has a place in the treatment of patients with increased risk of cardiovascular events.

Original languageEnglish (US)
Pages (from-to)1-9
Number of pages9
JournalExpert Opinion on Drug Safety
DOIs
StateAccepted/In press - Jul 27 2017
Externally publishedYes

Fingerprint

Type 2 Diabetes Mellitus
Safety
Gastrointestinal Agents
Drug Approval
Injections
Glucagon-Like Peptide 1
Expert Testimony
European Union
Therapeutics
PubMed
Pancreatitis
Renal Insufficiency
Weight Loss
Placebos
Food
rGLP-1 protein

All Science Journal Classification (ASJC) codes

  • Pharmacology (medical)

Cite this

The safety of albiglutide for the treatment of type 2 diabetes. / Rendell, Marc S.

In: Expert Opinion on Drug Safety, 27.07.2017, p. 1-9.

Research output: Contribution to journalArticle

@article{a45d34e445dc4d3bba538ba078b7c772,
title = "The safety of albiglutide for the treatment of type 2 diabetes",
abstract = "Introduction: Albiglutide is a marketed long acting GLP-1 receptor agonist (GLP-1 RA) administered by weekly injection. It has significantly less gastrointestinal side effects than other GLP-1 RAs in current use but does not improve HbA1c or promote weight loss to the same extent as competitor agents such as liraglutide. Area Covered: The safety of albiglutide is discussed. The review encompassed a search of PubMed and a thorough analysis of the European Union and US Food and Drug Administration approval documents. Expert Opinion: Unlike competitor agents, the gastrointestinal side effects of albiglutide are not much greater than placebo. It has been studied and appears safe at all stages of renal failure. There exists concern about an imbalance of pancreatitis cases in the approval program as well as injection site reactions which led to discontinuance of therapy in up to 2{\%} of participants. A large long term study now underway will determine if albiglutide, with its relatively favorable GI tolerance, has a place in the treatment of patients with increased risk of cardiovascular events.",
author = "Rendell, {Marc S.}",
year = "2017",
month = "7",
day = "27",
doi = "10.1080/14740338.2017.1351538",
language = "English (US)",
pages = "1--9",
journal = "Expert Opinion on Drug Safety",
issn = "1474-0338",
publisher = "Informa Healthcare",

}

TY - JOUR

T1 - The safety of albiglutide for the treatment of type 2 diabetes

AU - Rendell, Marc S.

PY - 2017/7/27

Y1 - 2017/7/27

N2 - Introduction: Albiglutide is a marketed long acting GLP-1 receptor agonist (GLP-1 RA) administered by weekly injection. It has significantly less gastrointestinal side effects than other GLP-1 RAs in current use but does not improve HbA1c or promote weight loss to the same extent as competitor agents such as liraglutide. Area Covered: The safety of albiglutide is discussed. The review encompassed a search of PubMed and a thorough analysis of the European Union and US Food and Drug Administration approval documents. Expert Opinion: Unlike competitor agents, the gastrointestinal side effects of albiglutide are not much greater than placebo. It has been studied and appears safe at all stages of renal failure. There exists concern about an imbalance of pancreatitis cases in the approval program as well as injection site reactions which led to discontinuance of therapy in up to 2% of participants. A large long term study now underway will determine if albiglutide, with its relatively favorable GI tolerance, has a place in the treatment of patients with increased risk of cardiovascular events.

AB - Introduction: Albiglutide is a marketed long acting GLP-1 receptor agonist (GLP-1 RA) administered by weekly injection. It has significantly less gastrointestinal side effects than other GLP-1 RAs in current use but does not improve HbA1c or promote weight loss to the same extent as competitor agents such as liraglutide. Area Covered: The safety of albiglutide is discussed. The review encompassed a search of PubMed and a thorough analysis of the European Union and US Food and Drug Administration approval documents. Expert Opinion: Unlike competitor agents, the gastrointestinal side effects of albiglutide are not much greater than placebo. It has been studied and appears safe at all stages of renal failure. There exists concern about an imbalance of pancreatitis cases in the approval program as well as injection site reactions which led to discontinuance of therapy in up to 2% of participants. A large long term study now underway will determine if albiglutide, with its relatively favorable GI tolerance, has a place in the treatment of patients with increased risk of cardiovascular events.

UR - http://www.scopus.com/inward/record.url?scp=85025839169&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85025839169&partnerID=8YFLogxK

U2 - 10.1080/14740338.2017.1351538

DO - 10.1080/14740338.2017.1351538

M3 - Article

SP - 1

EP - 9

JO - Expert Opinion on Drug Safety

JF - Expert Opinion on Drug Safety

SN - 1474-0338

ER -